Phathom PharmaceuticalsPHAT
PHAT
About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Employees: 112
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
327% more call options, than puts
Call options by funds: $4.5M | Put options by funds: $1.05M
217% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 18
200% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 10
122% more capital invested
Capital invested by funds: $590M [Q2] → $1.31B (+$722M) [Q3]
33% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 12 (+3) [Q3]
18% more funds holding
Funds holding: 113 [Q2] → 133 (+20) [Q3]
8.46% more ownership
Funds ownership: 97.91% [Q2] → 106.37% (+8.46%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
276%
upside
Avg. target
$28
276%
upside
High target
$28
276%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target | 276%upside $28 | Buy Reiterated | 12 Dec 2024 |
Needham Joseph Stringer 31% 1-year accuracy 39 / 127 met price target | 276%upside $28 | Buy Reiterated | 11 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the full 10-year NCE exclusivity period until May 3, 2032.
Positive
Zacks Investment Research
2 weeks ago
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
1 month ago
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Seeking Alpha
1 month ago
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Paul Choi - Goldman Sachs Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call.
Negative
Zacks Investment Research
1 month ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:
Neutral
GlobeNewsWire
1 month ago
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
Neutral
GlobeNewsWire
1 month ago
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD), for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn, and in combination with antibiotics for the eradication of Helicobacter pylori (H. pylori) infection.1 VOQUEZNA is the first and only U.S. Food and Drug Administration (FDA)-approved potassium-competitive acid blocker (PCAB).2
Neutral
PRNewsWire
2 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty.
Neutral
GlobeNewsWire
3 months ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
Charts implemented using Lightweight Charts™